Status Plus




Dienogest for the treatment of dyspareunia caused by endometriosis

Pkhaladze, L1; Khomasuridze, A1; Marshania, Z2

1: Archil Khomasuridze Institute of Reproductology, Georgia; 2: Georgian Society for Sexual Medicine and Department of Sexual Medicine of “Enmedic”, Georgia

Objective: Dyspareunia - painful sexual intercourse is one of the common sexual dysfunction among women and it can be caused not only by psychogenic but organic diseases too, including endometriosis that affects 10%-15% of reproductive aged women. Possibility of treatment dyspareunia among women suffered with endometriosis is valuable for Improvement of female's quality of life. The aim of our study was to evaluate the efficacy of dienogest for the treatment of dyspareunia caused by endometriosis.

Methods: 34 women aged 18-39 years (the average age in study group was 32±4.1) with endometriosis (confirmed by clinical and/or ultrasound and/or laparoscopy) suffered from dyspareunia were included in the prospective open-label clinical study. Criteria for exclusion were other treatment before 6 month and existence of pelvic inflammatory disease. Patients received 2 mg dienogest for 6 month. Pain score during sexual intercourses were evaluated by using 100 mm visual analog scale(VAS) before and after 3 and 6 month of treatment.

Results: Average baseline score before treatment was 8.4±0.7 cm. After 3 month of treatment with dienogest the intensity of pain decreased up to 4.5±1.2 cm(p<0.05). After 6 month of treatment decreasing of average score was more significant and totals 1.4±0.5cm (p<0.05).

Conclusion: Dienogest statistically reliable decreased intensity of pain during the sexual intercourse among women with endometriosis. Consequently above-mentioned treatment could be proposed as a first line therapy of reproductive aged women with dyspareunia caused by endometriosis.  


Work supported by industry: no.

Go Back